Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antihistamine |
| gptkbp:approvedBy |
1990s
|
| gptkbp:ATCCode |
R06AX22
|
| gptkbp:availableOn |
gptkb:tablet
oral suspension |
| gptkbp:brand |
Ebastel
Ebatil Kestine |
| gptkbp:CASNumber |
90729-43-4
|
| gptkbp:contraindication |
severe liver impairment
|
| gptkbp:developedBy |
gptkb:Almirall
|
| gptkbp:drugClass |
second-generation antihistamine
|
| gptkbp:eliminationHalfLife |
15-19 hours
|
| gptkbp:hasMolecularFormula |
C32H39NO2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ebastine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
H1 receptor antagonist
|
| gptkbp:metabolism |
carebastine
|
| gptkbp:pregnancyCategory |
Category B (Australia)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
drowsiness dry mouth |
| gptkbp:usedFor |
gptkb:chronic_idiopathic_urticaria
allergic rhinitis |
| gptkbp:bfsParent |
gptkb:Other_antihistamines_for_systemic_use
gptkb:Este_tablets |
| gptkbp:bfsLayer |
7
|